Cargando…

Biosimilar biological drugs in the treatment of inflammatory bowel diseases

Within the last 20 years, tumour necrosis factor inhibitors have been proven to be effective in achieving and maintaining clinical and endoscopic remission in patients with Crohn’s disease and ulcerative colitis. Since 2013, when infliximab originator lost its patent protection, patients with inflam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaniewska, Magdalena, Eder, Piotr, Gąsiorowska, Anita, Gonciarz, Maciej, Kierkuś, Jarosław, Małecka-Panas, Ewa, Rydzewska, Grażyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2019
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983762/ https://www.ncbi.nlm.nih.gov/pubmed/31988667 http://dx.doi.org/10.5114/pg.2019.90093

Ejemplares similares

Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology
por: Mularczyk, Aldona, et al.
Publicado: (2014)

Iron deficiency anaemia in patients with inflammatory bowel disease: National Consultant for Gastroenterology Working Group Recommendations
por: Kaniewska, Magdalena, et al.
Publicado: (2014)

New pharmaceuticals in inflammatory bowel disease
por: Łodyga, Michał, et al.
Publicado: (2015)

The efficacy and safety of the biosimilar product (Inflectra(®)) compared to the reference drug (Remicade(®)) in rescue therapy in adult patients with ulcerative colitis
por: Kaniewska, Magdalena, et al.
Publicado: (2017)

Biosimilars in paediatric inflammatory bowel disease
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2018)

The Use of Virtual Reality to Reduce Stress among Inflammatory Bowel Disease Patients Treated with Vedolizumab
por: Lewandowski, Konrad, et al.
Publicado: (2021)

The introduction of the IBD Disk in Poland – a new tool for assessing disability in patients with inflammatory bowel disease
por: Eder, Piotr, et al.
Publicado: (2019)

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
por: Kaniewska, Magdalena, et al.
Publicado: (2020)

Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik
por: Pietrzak, Anna, et al.
Publicado: (2018)

Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology
por: Łodyga, Michał, et al.
Publicado: (2021)

Social Distancing during COVID-19 Pandemic among Inflammatory Bowel Disease Patients
por: Łodyga, Michał, et al.
Publicado: (2021)

Selected Aspects of Nutrition in the Prevention and Treatment of Inflammatory Bowel Disease
por: Panufnik, Paulina, et al.
Publicado: (2022)

Biological markers of disease activity in inflammatory bowel diseases
por: Szymanska, Edyta, et al.
Publicado: (2023)

Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature
por: Wlazło, Magdalena, et al.
Publicado: (2022)

The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review
por: Daniluk, Jaroslaw, et al.
Publicado: (2022)

Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology
por: Eder, Piotr, et al.
Publicado: (2023)

Position statement of the Polish Society of Gastroenterology and the National Gastroenterology Consultant on vaccination against COVID-19 among patients with inflammatory bowel diseases
por: Eder, Piotr, et al.
Publicado: (2021)

The position statement of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic
por: Łodyga, Michał, et al.
Publicado: (2020)

Low-FODMAP Diet for the Management of Irritable Bowel Syndrome in Remission of IBD
por: Więcek, Martyna, et al.
Publicado: (2022)

The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome
por: Lewandowski, Konrad, et al.
Publicado: (2022)

The prevalence, characteristics, and determinants of anaemia in newly diagnosed patients with inflammatory bowel disease
por: Woźniak, Małgorzata, et al.
Publicado: (2019)

Leukocytapheresis in patients with inflammatory bowel diseases
por: Woźniak, Małgorzata, et al.
Publicado: (2021)

Insulin-like growth factor 1 and insulin-like growth factor binding protein 2 serum levels as potential biomarkers in differential diagnosis between chronic pancreatitis and pancreatic adenocarcinoma in reference to pancreatic diabetes
por: Włodarczyk, Barbara, et al.
Publicado: (2020)

Risk Factors for Osteoporosis among Patients with Inflammatory Bowel Disease—Do We Already Know Everything?
por: Lewandowski, Konrad, et al.
Publicado: (2023)

Determinants of Sleep Quality in Inflammatory Bowel Diseases
por: Sochal, Marcin, et al.
Publicado: (2020)

Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study
por: Wlazło, Magdalena, et al.
Publicado: (2022)

Diagnostic and therapeutic recommendations for chronic pancreatitis. Recommendations of the Working Group of the Polish Society of Gastroenterology and the Polish Pancreas Club
por: Kadaj-Lipka, Roland, et al.
Publicado: (2018)

The risk of cardiovascular complications in inflammatory bowel disease
por: Czubkowski, Piotr, et al.
Publicado: (2020)

Diagnostic and therapeutic recommendations on Helicobacter pylori infection. Recommendations of the Working Group of the Polish Society of Gastroenterology
por: Jaroń, Krzysztof, et al.
Publicado: (2023)

Quality of life and depression in patients with irritable bowel syndrome
por: Kopczyńska, Magdalena, et al.
Publicado: (2018)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

Gastrointestinal symptoms in COVID-19
por: Lewandowski, Konrad, et al.
Publicado: (2022)

Biomarkers in management of inflammatory bowel disease
por: Moniuszko, Andrzej, et al.
Publicado: (2013)

Demographic characteristics of children with early clinical manifestation of inflammatory bowel disease
por: Szymańska, Edyta, et al.
Publicado: (2015)

Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club
por: Winter, Katarzyna, et al.
Publicado: (2019)

The prevalence of celiac disease in patients with irritable bowel syndrome and its subtypes
por: Domżał-Magrowska, Danuta, et al.
Publicado: (2016)

Skin and gastrointestinal symptoms in COVID-19
por: Ciechanowicz, Piotr, et al.
Publicado: (2020)

Sexual functions in individuals with inflammatory bowel diseases
por: Kotkowicz-Szczur, Marta, et al.
Publicado: (2023)

Assessment of sexual dysfunction in patients with inflammatory bowel disease
por: Szydlarska, Dorota, et al.
Publicado: (2019)

The Prevalence of Cationic Trypsinogen (PRSS1) and Serine Protease Inhibitor, Kazal Type 1 (SPINK1) Gene Mutations in Polish Patients with Alcoholic and Idiopathic Chronic Pancreatitis
por: Gasiorowska, Anita, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_8ui3fiu0oi5hvs9lv4l0ghr5bs